DTX3L and prostate carcinoma: The overexpression of DTX3L promotes the phosphorylation of STAT1 and represses the transcription of IFN regulatory factor-1 (IRF-1), thus enhancing the proliferation, metastasis and chemoresistance of prostate cancer cells [19].